RNA-seq in drug discovery and development
Author(s)
Bibliographic Information
RNA-seq in drug discovery and development
(Drugs and the pharmaceutical sciences)
CRC Press, 2024
- : HB
Available at 2 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
One of the few books that focuses on the applications of the RNA seq technique in drug discovery and development.
Comprehensive and timely publication which relates RNA sequencing to drug targets, mechanisms of action and resistance
The editor has extensive experience in the field of computational medicinal chemistry, computational biophysics and bioinformatics.
Chapter authors are at the frontline of the academic and industrial science in this particular area of RNA sequencing
Table of Contents
Chapter 1: Introduction to RNA-Sequencing and Quality Control
1.1: What is RNA-Sequencing?
1.2. Overview of RNA-sequencing
1.2.1. Isolation of the RNA and RNA quality check
1.2.2 Selection and depletion of particular RNA
1.2.3 Fragmentation
1.2.4 Reverse transcription to generate cDNA and adaptor sequences
1.2.5 Single-end and Pair-end Sequencing
1.3. RNA-seq Sequencing techniques:
1.3.1 Roche 454
1.3.2 Illumina platform
1.3.3 Small-scale RNA-seq platform
1.4. RNA-seq file format
1.4.1 Output file: Fastq file
1.4.2 Mapped file: SAM/BAM/BIGWIG formats
1.4.3 GTF file
1.4.4 BED File
1.5. Quality control of RNA-seq Data
1.5.1 Basic Usage of the Public Server Galaxy
1.5.2 FastQC program
1.6. Advantages of RNA-seq over microarrays
1.7. Summary
Chapter 2: Read Alignment and Transcriptome Assembly
2. Introduction
2.1 Transcriptome Assembly Methodology
2.1.1 De novo assembly
2.2 Genome-guided Assembly
2.2.1 Unspliced Aligners: Burrows-Wheeler Transform (BWT)
2.2.2 Unspliced Aligners: Seed Methods
2.3 Spliced Aligners
2.3.1 TopHat
2.3.2 HISAT2
2.3.3 STAR
2.4 Summary
Chapter 3: Normalization and Downstream Analyses
3.1 Introduction
3.2 Quantification of Transcript Abundance
3.3 Raw Counts Extraction
3.3.1 Rsubread and featurecounts
3.3.2 Normalization Methods
3.4 Differential gene expression analysis
3.4.1 DESeq2
3.4.2 EdgeR
3.4.3 Ballgown
3.5. Visualization of differential expression
3.5.1 Integrative Genomics Viewer (IGV)
3.5.2 UCSC Genome Browser
3.5.3 Heatmaps
3.5.4 Volcano Plots
3.5.5 DAVID Pathway Analysis
3.6. Summary
Chapter 4: Constitutive and Alternative Splicing Events
4.1. Introduction to RNA splicing
4.1.1 What is splicing?
4.1.2 Molecular mechanism of splicing
4.1.3 Alternative Splicing
4.2. Differential splicing analysis
4.2.1 Cuffdiff 2
4.2.2 DiffSplice
4.2.3 DEXSeq
4.2.4 edgeR
4.2.5 LIMMA
4.3. Summary
Chapter 5: The role of transcriptomics in identifying fusion genes and chimeric RNAs in cancer
5.1 Introduction to fusion genes
5.1.1 What is a fusion gene?
5.1.2 Mechanisms that generate new fusion genes
5.1.3 Fusion RNA transcripts
5.1.4 The connection between fusion genes and non-coding RNAs
5.2 Detection methods for identification of fusion genes and chimeric proteins
5.2.1 Guided detection approaches
5.2.2 High-throughput sequencing-based detection methods
5.3 Summary
Chapter 6: MiRNA and RNA-seq
6.1 Non-coding RNAs
6.2 MiRNAs
6.3 LncRNAs
6.4 miRDeep2
6.5 Applications
6.6 Summary
Chapter 7: Toxicogenomics and RNA-seq
7.1 Introduction of toxicity
7.1.1 Traditional toxicity study
7.2 Toxicogenomics
7.2.1 What is Toxicogenomics?
7.2.2 Advantages: Mechanisms and predictive toxicology
7.2.3 Mechanisms of toxicity:
7.2.4 Limitations of toxicogenomics:
7.3 Methods for toxicogenomics data analysis
7.3.1 Identification of Differentially expressed genes
7.3.2 Signature matching
7.3.3 Gene Networks
7.3.4 Co-expression networks
7.4 Toxicogenomics databases
7.4.1 Comparative Toxicogenomics Database (CTD)
7.4.2 Japanese Toxicogenomics Project (TGP)
7.4.3 DrugMatrix
7.5 Comparing microarray vs. RNA-seq
7.6 Summary
Chapter 8: Drug Discovery and Traditional Medicine
8.1 Introduction
8.2 What is herbal medicine?
8.2.1 Traditional medicine
8.2.2 Herbal medicine
8.2.3 Use of database for bioactive compound example
8.2.4 Properties of candidate herbal compounds
8.2.5 RNA-seq and herbal medicine
8.3 Mining functional genes of medicinal plants
8.3.1 Mining functional genes of medicinal plants
8.3.2 Discovery of secondary metabolites and their metabolic pathways
8.3.3 Discovery of developmental mechanisms
8.3.4 Development of molecular markers to improve plant breeding
8.3.5 Identification of target genes and molecular mechanisms of herbal drugs
8.3.6 Synergism of herbal compounds in pathway regulation
8.3.7 Herbal medicine toxicity
8.3.8 Natural drug repurposing
8.4 Summary
Chapter 9: Single-Cell RNA-sequencing
9. Introduction to single-cell sequencing
9.1 Microdroplet approaches to cell capture
9.2 Non-microfluidic approaches to cell capture
9.3 Single-cell processing: Cell Ranger
9.4 STARsolo
9.5 DropletUtils
9.6 Seurat
9.7 Limitations
9.8 Applications
9.9 Summary
by "Nielsen BookData"